Latest Hospital Cancer Center Stories

Proof-of-concept animal study selected as one of the best presentations at 54(th) American Society of Hematology Annual Meeting and Exposition BOSTON, Dec. 11, 2012 /PRNewswire-USNewswire/ -- Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) have taken the first preliminary steps toward developing a form of gene therapy for sickle cell disease. In an abstract presented on Dec. 10 at the 54(th) annual meeting of the American Society of Hematology, the research...

Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston. The trial leaders will present the results of the Dana-Farber Cancer Institute ALL Consortium study, which involved nearly 500 patients under age 18 with B-precursor acute...

Findings could enable individualized treatment for patients with medulloblastoma BOSTON, July 22, 2012 /PRNewswire-USNewswire/ -- Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and several collaborating institutions have linked mutations in specific genes to each of the four recognized subtypes of medulloblastoma, the most common malignant brain tumor of children. The discovery, reported July in the journal Nature, provides doctors with potential biomarkers...

Study documents connection between increased levels of these lipids and cancer growth and metastasis; also opens door to new avenue for cancer treatment BOSTON, Dec. 19, 2011 /PRNewswire-USNewswire/ -- A group of small molecules called EETs - currently under scrutiny as possible treatment targets for a host of cardiovascular diseases - may also drive the growth and spread of cancer, according to researchers at the Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and other...

Researchers to discuss their stimulus-funded project at Boston conference BOSTON, Oct. 22 /PRNewswire-USNewswire/ -- The National Institutes of Health has awarded a three-year, $3.9 million grant to Children's Hospital Boston researchers and their colleagues to develop a therapy to treat Fanconi anemia, a fatal genetic blood disease. The researchers will investigate new ways to create induced pluripotent stem (iPS) cells from a patient's skin or other tissue and transform them into...